While the precise consequences of the PINK1 and Parkin impairments that are most important in relation to dopaminergic neurodegeneration still remain to be determined, enhancement of PINK1 and Parkin activity is an attractive avenue for novel disease-modifying therapies in PD. This evidence concerns the gene PINK1 and Parkinson disease.